moonlake immunotherapeutics mltx has reportedly engaged an investment bank as the swiss company looks for a potential sale the company focuses on developing antibodyderived treatments for inflammatory skin conditions the is in preliminary talks with pharmaceutical companies interested in a potential acquisition citing the sources reuters emphasized that a deal isnt guaranteed and wished to remain anonymous companies specializing in immunology have been popular acquisition targets as indicated by recent acquisitions such as merck  co incs mrk purchase of prometheus biosciences inc and eli lilly and cos lly acquisition of dice therapeutics inc dice also read cantor on moonlake immunotherapeutics  initiates on inexpensive valuation strong catalyst path recently moonlake released topline results from its phase 2 mira trial evaluating the nanobody sonelokimab in patients with moderatetosevere hidradenitis suppurativa hs meeting its primary endpoint a few days later the company stated it had raised 400 million through a stock sale to continue funding the development of sonelokimab if successful moonlake could enter a market dominated by bigger players like novartis ag nvs and abbvie inc abbv moonlake was established in 2021 when merck kgaa licensed the firststage clinical development of sonelokimab to a newly created company in 2022 moonlake became a public company through a merger with a special purpose acquisition company spac raising over 200 million in cash since its market debut its share price has increased fivefold price action mltx shares are down 774 at 5007 during the premarket session on the last check monday